Upstream Bio (NASDAQ:UPB – Get Free Report) had its price target lowered by analysts at Mizuho from $51.00 to $50.00 in a research note issued to investors on Thursday,Benzinga reports. The firm presently has an “outperform” rating on the stock. Mizuho’s target price points to a potential upside of 434.19% from the stock’s previous close.
A number of other analysts have also issued reports on the stock. Wall Street Zen lowered shares of Upstream Bio from a “hold” rating to a “sell” rating in a research note on Saturday, March 28th. Evercore downgraded Upstream Bio from an “outperform” rating to an “in-line” rating and set a $15.00 price target on the stock. in a report on Friday, March 27th. Finally, Weiss Ratings lowered shares of Upstream Bio from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, May 6th. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $38.75.
Upstream Bio Price Performance
Upstream Bio (NASDAQ:UPB – Get Free Report) last announced its earnings results on Wednesday, May 13th. The company reported ($0.75) EPS for the quarter, topping analysts’ consensus estimates of ($0.79) by $0.04. Upstream Bio had a negative return on equity of 36.48% and a negative net margin of 5,026.03%.The firm had revenue of $1.03 million during the quarter, compared to analysts’ expectations of $0.62 million. Equities research analysts expect that Upstream Bio will post -3.06 EPS for the current year.
Hedge Funds Weigh In On Upstream Bio
Several hedge funds have recently made changes to their positions in the company. GF Fund Management CO. LTD. purchased a new position in Upstream Bio in the 4th quarter worth $29,000. Torren Management LLC acquired a new position in shares of Upstream Bio in the fourth quarter valued at about $30,000. BNP Paribas Financial Markets raised its stake in shares of Upstream Bio by 229.8% in the second quarter. BNP Paribas Financial Markets now owns 3,097 shares of the company’s stock worth $34,000 after purchasing an additional 2,158 shares during the last quarter. Legal & General Group Plc lifted its holdings in shares of Upstream Bio by 83.0% during the second quarter. Legal & General Group Plc now owns 3,174 shares of the company’s stock worth $35,000 after purchasing an additional 1,440 shares during the period. Finally, Empowered Funds LLC purchased a new stake in Upstream Bio in the fourth quarter valued at approximately $45,000.
Upstream Bio Company Profile
Upstream Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation prophylactic vaccines and immuno-oncology therapies. Leveraging a proprietary viral vector platform, the company aims to deliver optimized antigen payloads that stimulate robust and durable immune responses against both infectious diseases and cancer targets. Upstream Bio’s approach emphasizes safety, manufacturability and potential for rapid scale-up to address emerging public health challenges.
The company’s research and development pipeline includes multiple viral vector-based candidates in early clinical and preclinical stages.
Read More
- Five stocks we like better than Upstream Bio
- How Berkshire’s New York Times Bet Looks Today
- Affirm’s Google Deal Aims for Your Wallet
- Airplane Maintenance Companies That Keep Flights Moving Are Ready to Soar
- Oklo Stock Could Be Ready for Another Massive Run
Receive News & Ratings for Upstream Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Upstream Bio and related companies with MarketBeat.com's FREE daily email newsletter.
